Novelogics Welcomes Dr. Neil Clendeninn as Chief Medical Officer to Drive their Lead Candidate to the Clinic
VANCOUVER, BC – Novelogics Biotechnology Inc. is welcoming Dr. Neil Clendeninn as the company’s Chief Medical Officer. Dr. Clendeninn is an accomplished Senior Executive, Consultant, and Board Member with more than 35 years of success across the pharmaceutical, biotech, and medical industries. Click Here for more information.
Novelogics Selected to Present at Keiretsu Angel Expo
REDMOND, WA – Aug 6, 2019 – Novelogics is excited to announce they have been selected by the Deal Screening Committee to present at Keiretsu Angel Expo in Redmond, WA on August 22, 2019. More information here:
Novelogics Issued Patents in Japan and AustraliaVANCOUVER, BC – June 28, 2019 – Novelogics has been issued patents for its revolutionary technology in both Japan and Australia.
Novelogics Wins “Most Innovative Company” at Angel Forum April 2019
VANCOUVER, BC – April 16, 2019 – More information here:
Novelogics Biotechnology Inc. wins “Best Pre-Revenue Company” at the 44th edition, Angel Forum – Vancouver (award presented by PwC)
VANCOUVER, BC – November 6, 2018 – For more information visit:
Scott Cormack Joins Board of Directors of Novelogics to Expand Growth Plans
Vancouver, BC – February 13, 2018 – Novelogics Biotechnology, Inc. announced today that the Company has appointed Mr. Scott D. Cormack to its Board of Directors.
Novelogics wins “1st Runner Up” at Banff Venture Forum 2017
Banff, AB – September 29, 2017 – For more information visit: http://banffventureforum.com/
Novelogics Biotechnology Inc. wins “Best Pre-Revenue Company” as voted by 55+ investors at the 41st, BC Angel Forum
VANCOUVER, BC – June 14th, 2017 – For more information visit: http://www.angelforum.org/cpages/home
Novelogics Biotechnology Inc. receives NRC/IRAP contribution for the development of new cancer treatment
VANCOUVER, BC- January, 2015 – Novelogics Biotechnology Inc. would like to report that it has received a financial contribution from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) of up to $134,800 to aid in the development of Novelogics’ new approach to fighting cancer. The objective of the cancer treatment project is to complete a proof-of-concept and transition into pre-clinical development in order to continue to progress their approach through to 2016.
Novelogics Biotechnology Inc. receives Government of Canada support for the development of new cancer treatment
VANCOUVER, BC- August 7, 2013 – Novelogics Biotechnology Inc. announced today that it has received a financial contribution from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) of up to $50,000 to aid in the development of Novelogics’ new approach to fighting cancer. The objective of the cancer treatment project is to complete a proof-of-concept study that validates the approach by mid-2014.